Products
Emicizumab Biosimilar Bispecific Antibody (Factor IX × Factor X) for Research
Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of Roche). A Phase I clinical trial found that it was well tolerated by healthy subjects.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-177-1mg | 1mg | |
| GMP-Bios-ab-177-10mg | 10mg | |
| GMP-Bios-ab-177-100mg | 100mg | |
| GMP-Bios-ab-177-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Emicizumab biosimilar, Bispecific mAb, Anti-F9;F10 Antibody: Anti-FIX/HEMB/P19/PTC/THPH8;FX/FXA therapeutic antibody |
| INN Name | Emicizumab |
| Target | F9;F10 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG4;G4 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | NFD |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Chugai Pharmaceutical;Roche |
| Conditions Approved | Haemophilia A |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - F9
1. Protein Coagulation factor IX
2. Gene F9
3. Organism Homo sapiens (Human)
Function
Factor IX is a vitamin K-dependent plasma protein that participates in the intrinsic pathway of blood coagulation by converting factor X to its active form in the presence of Ca2+ ions, phospholipids, and factor VIIIa.
Miscellaneous
In 1952, one of the earliest researchers of the disease, Dr. R.G. Macfarlane used the patient's surname, Christmas, to refer to the disease and also to refer to the clotting factor which he called the 'Christmas Factor' At the time Stephen Christmas was a 5-year-old boy. He died in 1993 at the age of 46 from acquired immunodeficiency syndrome contracted through treatment with blood products.
Catalytic activity
Selective cleavage of Arg-|-Ile bond in factor X to form factor Xa.
